News

Jerusalem, Israel, January 6, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted approval of the company's ANDA for Metolazone Tablets, 2.5 mg and 10 mg. Metolazone Tablets are the AB-rated generic equivalent of Celltech's Zaroxolyn® Tablets which are indicated for the treatment of edema and hypertension.Annual sales of these strengths of the brand product are approximately $40 million. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 30 pharmaceutical companies and among the largest gen Read More »

Companies To Complete Deal Within Several Business DaysJerusalem, Israel and Irvine, California, January 18, 2004 - Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA) and SICOR Inc. (Nasdaq: SCRI) announced that they have been advised by the Federal Trade Commission that early termination of the Hart-Scott-Rodino waiting period has been granted with respect to the proposed acquisition of SICOR by Teva. On Friday, January 16, 2004, the stockholders of SICOR voted to approve the merger.The parties expect to complete the transaction within the next several business days. Teva Pharmaceutical Indu Read More »

Jerusalem, Israel, January 21, 2004 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that, subject to market and other conditions, Teva Pharmaceutical Finance II, LLC, a special purpose finance subsidiary, intends to offer approximately $1 billion of twenty-year convertible senior debentures. The debentures will be offered in two series.In addition, the underwriters have been granted an option to purchase an additional $ 150 million of debentures to cover overallotments.The debentures are expected to be guaranteed by Teva and to be convertible into American Depositary Re Read More »

Jerusalem, Israel, January 22, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has completed its acquisition of Sicor Inc. (Nasdaq: SCRI), which was previously announced on October 31, 2003 and approved by Sicor's shareholders on January 16, 2004. Israel Makov, Teva's President & CEO, commented, "We are proud to announce the completion of this transaction, which marks an important milestone for Teva. This acquisition brings together two premier generic pharmaceutical companies and further enhances Teva's position of leadership within the industry. Our Read More »

Jerusalem, Israel, January 22, 2004 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that Teva Pharmaceutical Finance II, LLC ("Teva Finance"), a special purpose finance subsidiary, priced its offering of $400 million in aggregate principal amount of 0.50% Series A Convertible Senior Debentures due 2024 and $600 million in aggregate principal amount of 0.25% Series B Convertible Senior Debentures due 2024, in each case, guaranteed by Teva. The debentures are convertible into American Depositary Receipts of Teva at the conversion price of U.S. $75.80 per ADR, a Read More »

Jerusalem, Israel, January 31, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the United States Court of Appeals for the Federal Circuit has vacated a March 24, 2003 summary judgment decision by the U.S. District Court for the District of New Jersey, which had found that Teva's product, Moexipril HCl Tablets would not infringe U.S. Patent No. 4,743,450, asserted by Schwarz Pharma as licensee of Warner Lambert. The Court of Appeals has remanded the case to the District Court for further proceedings, which will involve Teva's allegations of inequitable conduct, in Read More »

Conference Call Scheduled For 09:00 Am EstJerusalem, Israel, February 1, 2004 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it will release its fourth quarter and full year 2003 financial results on Tuesday, February 17, 2004, early in the morning (EST). The earnings release will be available on Teva's web site at www.tevapharm.com.Teva will host a conference call and live webcast on that same day, at 09:00AM EST to discuss its fourth quarter results and overall business environment. A Question & Answer session will follow this discussion. As announced on Januar Read More »

Jerusalem, Israel, February 5, 2004 - Teva Pharmaceutical Industries Limited (Nasdaq: TEVA) announced today that the underwriters of the recently completed public offering of convertible debentures of Teva Pharmaceutical Finance II, LLC ("Teva Finance"), a special purpose finance subsidiary, have exercised their option to purchase an additional $94.45 million in aggregate principal amount of debentures. Specifically, the underwriters will purchase an additional $60 million in principal amount of 0.50% Series A Convertible Senior Debentures due 2024 and an additional $34.45 million in Read More »

Jerusalem, Israel, February 11, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Benazepril Hydrochloride Tablets, 5 mg, 10 mg, 20 mg and 40 mg. Shipment of this product is expected to begin immediately.Benazepril Hydrochloride Tablets are the AB-rated generic equivalent of Novartis' antihypertensive agent Lotensin® Tablets. Annual sales of the brand product are approximately $335 million.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 30 phar Read More »

Record Annual Sales of $ 3.3 BillionJerusalem, Israel, February 17, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income of $186 million for the fourth quarter of 2003, up 36% over the comparable quarter of 2002, fully diluted EPS of $0.62, up 24%, and net sales for the quarter of $942 million, up 22%. For the full year of 2003, net sales were $3.3 billion, an increase of 30%. Net income and fully diluted EPS for the full year (including one-time net income of $73.2 million or $0.26 per ADR, recorded in the second quarter of 2003), amounted to $691 million and $2 Read More »